EcoDrugPlus

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSOTSG00005008273
Gene Symbol: RELA
1 Cross references
194 Possible Orthologues:

Vascular Endothelial Growth Factor A-A

Ensembl ID : ENSOTSG00005004156
Gene Symbol: LOC112223181
3 Cross references
173 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSOTSG00005041082
Gene Symbol: LOC112217670
3 Cross references
195 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSOTSG00005005278
Gene Symbol: LOC112234081
3 Cross references
175 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSOTSG00005028785
Gene Symbol: VEGFAB
1 Cross references
195 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSOTSG00005047692
Gene Symbol: VDR
3 Cross references
382 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSOTSG00005011283
Gene Symbol: VDR
3 Cross references
382 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSOTSG00005015166
Gene Symbol: LOC112253079
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-1-Like

Ensembl ID : ENSOTSG00005032353
Gene Symbol: LOC112258605
3 Cross references
203 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-3-Like

Ensembl ID : ENSOTSG00005025193
Gene Symbol: LOC112215796
3 Cross references
187 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSOTSG00005033143
Gene Symbol: LOC112238503
3 Cross references
198 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSOTSG00005045339
Gene Symbol: LOC112225596
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).